Alto Neuroscience Announces Peer-Reviewed Publication In The Journal Of Clinical Psychiatry Demonstrating Baseline Cognitive Performance Is Not A Moderator Of Response To Standard-Of-Care Antidepressants
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience published a study in The Journal of Clinical Psychiatry showing that baseline cognitive performance does not affect the response to standard antidepressants in MDD patients. Despite cognitive benefits, vortioxetine does not improve depressive symptoms in patients with cognitive impairment.
September 04, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alto Neuroscience's study indicates that baseline cognitive performance is not a factor in the effectiveness of standard antidepressants for MDD. This highlights the potential of ALTO-100 for depression with cognitive issues.
The publication supports Alto's focus on developing ALTO-100 for depression with cognitive impairment, potentially boosting investor confidence in its pipeline. The study's findings may not directly impact current revenues but highlight future growth potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80